Article
The CDK4/6 inhibitor revolution — a game-changing era for breast cancer treatment - Nature Reviews Clinical Oncology
Rating:
0.0
Views:
30
Likes:
1
Library:
1
Cyclin-dependent kinase (CDK) 4/6 inhibition in combination with endocrine therapy is the standard-of-care treatment for patients with advanced-stage hormone receptor-positive, HER2 non-amplified (HR+HER2−) breast cancer. These agents can also be administered as adjuvant therapy to patients with higher-risk early stage disease.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value